Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cardiol Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Cardiol Therapeutics Inc.’s stock price such as:

• Cardiol Therapeutics Inc.’s current stock price and volume
• Why Cardiol Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for CRDL from analysts
• CRDL’s stock price momentum as measured by its relative strength

About Cardiol Therapeutics Inc. (CRDL)

Before we jump into Cardiol Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Want to learn more about Cardiol Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cardiol Therapeutics Inc..

Cardiol Therapeutics Inc.’s Stock Price as of Market Close

As of November 28, 2025, 11:31 AM, CST, Cardiol Therapeutics Inc.’s stock price was $1.035.

Cardiol Therapeutics Inc. is up 0.49% from its previous closing price of $1.030.

During the last market session, Cardiol Therapeutics Inc.’s stock traded between $1.020 and $1.050. Currently, there are approximately 60.83 million shares outstanding for Cardiol Therapeutics Inc..

Cardiol Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cardiol Therapeutics Inc. Stock Price History

Cardiol Therapeutics Inc.’s (CRDL) price is currently down 8.41% so far this month.

During the month of November, Cardiol Therapeutics Inc.’s stock price has reached a high of $1.160 and a low of $0.940.

Over the last year, Cardiol Therapeutics Inc. has hit prices as high as $1.670 and as low as $0.771. Year to date, Cardiol Therapeutics Inc.’s stock is down 19.14%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cardiol Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there were 0 analysts who downgraded Cardiol Therapeutics Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cardiol Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cardiol Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cardiol Therapeutics Inc. (CRDL) by visiting AAII Stock Evaluator.

Relative Price Strength of Cardiol Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Cardiol Therapeutics Inc. has a weighted four-quarter relative price strength of -11.10%, which translates to a Momentum Score of 23 and is considered to be Weak.

Want to learn more about how Cardiol Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cardiol Therapeutics Inc. Stock Price: Bottom Line

As of November 28, 2025, Cardiol Therapeutics Inc.’s stock price is $1.035, which is up 0.49% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cardiol Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.